What's Hot
View all perspectives
Dr. Rachel Tate uptoTate
4 years ago
Do you consistently address T2T in your axSpA patients in your clinical practice? List your measures below! #ACR20 @RheumNow
Janet Pope Janetbirdope
4 years ago
Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj
Dr. Antoni Chan synovialjoints
4 years ago
In the search for biomarkers in PsA, interesting study showing absolute lymphocyte count is negatively correlated with cardiovascular disease risk score and red cell distribution width and increases with TNF-Inhibitor Therapy @rheumnow #ACR20 Abstr#878
Mrinalini Dey DrMiniDey
4 years ago
Some great abstracts on #vaccine hesitancy in the #infection in #rheumaticdiseases poster session!
What's the greatest concern for patients offered #influenza & #pneumococcal vaccines?
How can we address these concerns & encourage vaccine uptake? Comment below!
#ACR20 @RheumNow
Dr. Rachel Tate uptoTate
4 years ago
T2T in clinical practice: Most axSpA pts had ≥1 annual ASDAS recorded, but target ID/LDA achieved in only 1/3 of pts at the first measurement. How do you address T2T in your practice? #ABS0879 #ACR20 @RheumNow https://t.co/Jy0mmqpHAb https://t.co/06fI10V3OZ
Eric Dein ejdein1
4 years ago
Great job by @Rheumnow's Dr. Jonathan Kay on CT-P17, ADA biosimilar in Abst#0800. Similar ACR20 83% rate for ADA and CT-P17 with similar safety profile. #ACR20.
Eric Dein ejdein1
4 years ago
Lots at #ACR20 on arthralgias w/ +CCP. Abst#760 shows bone erosions (BE) rare in these pts (4%), did not show higher risk of progression to IA (41% w BE vs 31% wo BE, p=0.4). Overall high progression, unclear if high enough # with BE for analysis. @RheumNow.
Mrinalini Dey DrMiniDey
4 years ago
Tracking CRP in the hyper-acute phase of admission for #COVID19 predictive of progression to critical illness- suggests trends of inflammatory biomarkers, not absolute admission values, may be most useful for triage & therapy.
Abs#0626 #ACR20 @RheumNow
https://t.co/E14y3e4ALi
Dr. Rachel Tate uptoTate
4 years ago
Dr. J. Walsh slide on PROs in PsA research. #ACR20 @RheumNow https://t.co/v4ufUdWufB
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.
An International Panel Weighs in on RA Studies from Day 1 at ACR
Dr. Jonathan Kay leads a panel of rheumatologists from Dublin, Australia, The Philippines, Boston and Baltimore to talk about several initial abstracts that caught their attention at ACR 2020. Panel participants: Dr. Richard Conway, Dr. David Liew, Dr. Sheila Reyes, Dr. Jeffrey Sparks and Dr. Eric Dein.
sheila RHEUMarampa
4 years ago
What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20
Dr. Rachel Tate uptoTate
4 years ago
Baseline characteristics differed between M/F pts w/ AS & nr-axSpA. Women were older at dz onset w/longer symptom duration & more joint dz and were less likely to be + HLA-B27 than men. Do you see this in your practice? #ABS0876 #ACR20 @RheumNow https://t.co/2goek1NiUW https://t.co/Uk8pmNP4Hr
Mrinalini Dey DrMiniDey
4 years ago
Patients with ARDs have incr. susceptibility to #infection. Real-world study shows suboptimal #influenza, #pneumococcal & #herpeszoster #vaccination coverage in these patients. Important to consider strategies to improve uptake.
Abs#0541 #ACR20 @RheumNow
https://t.co/GAapkzILvW
Richard Conway RichardPAConway
4 years ago
Dr Peral reports on intracellular crystal containing vacuoles in gout and CPP arthritis. Crystal containing vacuoles only seen in CPP arthritis. @rheumnow #ACR20 Abstr#666 https://t.co/ITQMXhjQt0
Poster Hall